Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04736875
Other study ID # 3
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2019
Est. completion date February 20, 2022

Study information

Verified date March 2022
Source Medifil AE
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Study of the features of hemodynamic and clinical maturation of the native arteriovenous fistula for hemodialysis.


Description:

This is a prospective, single-center, observational study, investigating the clinical and hemodynamic features of maturation of hemodialysis native arteriovenous fistula (AVF). Hemodynamic features under investigation are the diameter of the feeding brachial artery, volume of flow (VF) measured with transcutaneous Duplex ultrasound (DUS), resistivity index (RI), diameter and wall thickness of the efferent vein, measured at days 1, 2, 3, 4, 5, 6, 7, 14, 21, 30, 60 and 90 post creation. Clinical features of maturation are the time of first access successful cannulation and the performance of three consecutive adequate dialysis sessions.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date February 20, 2022
Est. primary completion date February 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria: 1. Hemodialysis patients 2. new native arteriovenous fistula (AVF) Exclusion Criteria: 1. Patients not eligible for AVF creation 2. Patients with non compensated heart failure New York Heart Association stages 3 and 4

Study Design


Intervention

Diagnostic Test:
Doppler ultrasound study
Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.

Locations

Country Name City State
Greece Mediterranean Hospital Glyfáda Attiki

Sponsors (3)

Lead Sponsor Collaborator
Medifil AE Democritus University of Thrace, National and Kapodistrian University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Volume flow Volume of flow in brachial artery in L/min day 1 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 2 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 3 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 4 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 5 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 6 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 7 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 14 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 21 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 28 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 60 post access creation
Primary Volume flow Volume of flow in brachial artery in L/min day 90 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 1 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 2 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 3 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 4 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 5 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 6 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 7 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 14 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 21 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 28 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 60 post access creation
Primary brachial artery diameter Diameter of the Brachial artery in mm day 90 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 1 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 2 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 3 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 4 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 5 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 6 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 7 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 14 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 21 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 28 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 60 post access creation
Primary Resistive index RI Calculation of the Resistive Index of the Brachial artery day 90 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 1 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 2 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 3 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 4 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 5 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 6 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 7 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 14 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 21 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 28 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 60 post access creation
Primary Diameter of the efferent vein Diameter of the the efferent vein in mm day 90 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 1 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 2 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 3 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 4 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 5 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 6 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 7 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 14 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 21 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 28 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 60 post access creation
Primary Wall thickness of the efferent vein Wall thickness of the efferent vein in mm day 90 post access creation
Secondary Time of first successful cannulation Time period between access creation and first successful cannulation for hemodialysis 30 and 60 days
Secondary Successful hemodialysis Three consecutive adequate hemodialysis sessions based on measurement of single pool kt/V 30 and 60 days
Secondary Primary patency Percentage of total patent arteriovenous fistulae without the need of additional interventions assessed by transcutaneous dopler ultrasound 6 months
Secondary Surgeon-Nephrologist access site selection concordance Record of the opinion regarding the site of vascular access creation between the nephrologist performing preoperative mapping and the surgeon performing access creation with the use of a questionaire At access creation (day 0)
See also
  Status Clinical Trial Phase
Completed NCT04087213 - Study of HemoCareā„¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD N/A
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease N/A
Withdrawn NCT01691196 - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed NCT01394341 - Liraglutide Treatment to Patients With Severe Renal Insufficiency Phase 4
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4
Completed NCT00307463 - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Phase 4
Recruiting NCT00155363 - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Phase 4
Completed NCT00234156 - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers N/A
Completed NCT00586131 - Arterial pH and Total Body Nitrogen Balances in APD Phase 4
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Recruiting NCT04575077 - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Recruiting NCT03862859 - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis Phase 4
Terminated NCT03661229 - Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device N/A
Completed NCT03288922 - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF N/A
Completed NCT02572882 - Gut Microbiome and p-Inulin in Hemodialysis N/A
Completed NCT02360748 - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients N/A